Figure 8. CE-355621 inhibits the growth of MET amplified, HGF-independent GTL-16 gastric cancer xenografts. (A) CE-355621 inhibits the growth of GTL-16 xenograft tumors. Tumor cells were injected subcutaneously and tumors were grown to about 100 mm³. 400 μg CE-355621 was administered i.p. on days 7 and 14 (arrow heads) into groups of 7 mice/group. Results are mean ± SEM *p < 0.001 (by Student’s t-test) (B) Pharmacodynamic effects of CE-355621 on c-Met in GTL-16 xenograft tumors. Mice bearing GTL-16 tumors were dosed i.p. with 400 μg CE-355621. Tumors were excised 24 or 48 h later and lysates were prepared. The levels phosphoMet and total Met were determined by ELISA, using PY99 and sc-10 as detection reagents, respectively, and % inhibition relative to the untreated group was calculated. Values are the means ± SD from 4 animals per group.